Cover Image
市場調查報告書

角膜血管新生:開發中產品分析

Corneal Neovascularization - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246015
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
角膜血管新生:開發中產品分析 Corneal Neovascularization - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 39 Pages
簡介

所謂角膜血管新生是指眼球表面微小的血管增生、擴大。這些細小血管於鞏膜(眼白的部分)中的角膜接觸部分產生,擴大到眼睛表面,造成將來的視力喪失或眼睛受損。

本報告提供全球各國治療角膜血管新生治療所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 調查範圍

角膜血管新生概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

角膜血管新生:企業開發中的治療藥

角膜血管新生:大學/機關研究中的治療藥

角膜血管新生:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

角膜血管新生:企業開發中的產品

角膜血管新生:大學/機關研究中的產品

角膜血管新生的治療藥開發企業

  • Amakem NV
  • Gene Signal International SA
  • Sirnaomics, Inc.

角膜血管新生:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

角膜血管新生:最近的開發平台趨勢

角膜血管新生:暫停中的計劃

角膜血管新生:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8620IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Pipeline Review, H2 2016, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape.

Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Corneal Neovascularization - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 2 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively for Corneal Neovascularization.

Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Corneal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Corneal Neovascularization Overview
  • Therapeutics Development
    • Pipeline Products for Corneal Neovascularization - Overview
    • Pipeline Products for Corneal Neovascularization - Comparative Analysis
  • Corneal Neovascularization - Therapeutics under Development by Companies
  • Corneal Neovascularization - Therapeutics under Investigation by Universities/Institutes
  • Corneal Neovascularization - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Corneal Neovascularization - Products under Development by Companies
  • Corneal Neovascularization - Products under Investigation by Universities/Institutes
  • Corneal Neovascularization - Companies Involved in Therapeutics Development
    • Amakem NV
    • Gene Signal International SA
  • Corneal Neovascularization - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aganirsen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMA-0526 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Raver-2 Protein for Corneal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit Vascular Endothelial Growth Factor A for Corneal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDE-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Oncology and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Corneal Neovascularization - Dormant Projects
  • Corneal Neovascularization - Product Development Milestones
    • Featured News & Press Releases
      • May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation.
      • Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure
      • Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
      • Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Corneal Neovascularization, H2 2016
  • Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Corneal Neovascularization - Pipeline by Amakem NV, H2 2016
  • Corneal Neovascularization - Pipeline by Gene Signal International SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Corneal Neovascularization - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Corneal Neovascularization, H2 2016
  • Number of Products under Development for Corneal Neovascularization - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top